Table 1

p16 status of 36 primary T-ALL cells and their sensitivity to UCN-01a

Patient no.p16 statusbpRb statuscIC50 (nM)
19439muthyper27
29844deletionND27
330745deletionhypo6
431195deletionhyper37
531384deletionhyper2
631421deletionhyper54
731922deletionhyper11
832103deletionhyper96
932459deletionhyper37
1032564deletionNo pRb21
1132663deletionhyper126
1232691deletionhyper5
1332697deletionhyper80
14987deletionhyper25
1532810deletionhyper58
1632973deletionhyper5
1733174deletionND7
1833224deletionhyper39
1933241deletionND10
2033271deletionhyper73
2130496ddeletionhyper9
2231263mRNA−hyper2
2331380mRNA−hyper52
2432712mRNA−No pRb57
2532749mRNA−hyper250
261009protein−hyper36
279895protein−hyper16
130570p16+hyper778
230612p16+No pRb400
331390p16+hyper26
431474p16+hypo277
5958dp16+hyper210
632172p16+hyper67
732779p16+hypo500
81000p16+hypo42
933223p16+ND22
  • a T-ALL cells were treated increasing concentrations of UCN-01 for 3 days and then pulsed with[ 3H]thymidine for 6 h.

  • b mut, mutation; deletion, homozygous deletion; mRNA−, samples had neither detectable p16 mRNA nor protein despite retaining wild-type p16 gene; protein−, samples had no detectable p16 protein despite expressing wild-type of p16 mRNA; p16+, samples expressed wild-type p16 protein.

  • c hyper, hyperphosphorylated pRb; hypo, only hypophosphorylated pRb; ND, not determined.

  • d Relapse patient.